Slide 1: Investor Presentation
For personal use only Investor Presentation ASX:IPD July 2017
Slide 2: Disclaimer and Forward Looking Statements
Disclaimer and Forward Looking Statements For personal use only Disclaimer The material contained in this document is a presentation of general information about the activities of ImpediMed Limited (“ImpediMed”) current as at the date of this presentation. The information is provided in a summary fo
Slide 3: Investment Highlights
Investment Highlights For personal use only • Connected device for precisely measuring and monitoring tissue composition and fluid status using bioimpedance spectroscopy (BIS) technology for early detection and management of chronic disease (e.g. fluid build up in lymphoedema (L-Dex® score), fluid b
Slide 4: Corporate Overview
Corporate Overview For personal use only Share Register Breakdown • ASX listed (October 2007) 2% • Management Change July 2012 20% • S&P/ASX 300 – added March 2015 • Operations in US (San Diego, CA and Bloomington, MN), Australia (Brisbane) and Europe (Greece) (76 staff) 78% Institutional Private Fo
Slide 5: Bioimpedance Spectroscopy (BIS) Technology
Bioimpedance Spectroscopy (BIS) Technology For personal use only BIS Technology Advantages Low Frequency • Simple and sophisticated method for Fluid measuring fluid and tissue composition • Rapid, non-invasive Unique Spectra Fat • IPD’s full frequency spectrum (256 frequencies) approach uniquely Cur
Slide 6: SOZO – ImpediMed's State of the Art BIS Tool for Chronic Disease Management
SOZOTM – ImpediMed’s State of the Art BIS Tool for Chronic Disease Management For personal use only IPD Legacy BIS Measurement Tool (U400) SOZOTM – IPD State of the Art BIS Measurement Tool • Equivalent or superior accuracy compared with L-Dex® U400 and SFB7 • Highly sophisticated device that is uni
Slide 7: Cancer Survivors
For personal use only Cancer Survivors
Slide 8: L-Dex for the Early Detection of Lymphoedema
L-Dex® for the Early Detection of Lymphoedema For personal use only Lymphoedema is a leading post-surgical complication for many cancer patients and greatly impacts quality of life. Simple and accurate measurement of fluid in limbs allows early detection and intervention • Cancer treatment can damag
Slide 9: US Commercialisation of L-Dex Poised for Sustained Acceleration
US Commercialisation of L-Dex® Poised for Sustained Acceleration For personal use only • 100+ major multi-disciplinary cancer centres have incorporated L-Dex® • Currently using IPD’s FDA cleared U400 device • Purpose is to integrate L-Dex® testing into clinical work flow practices and systems in pre
Slide 10: Introduction of Private Payors will Further Drive Acceleration
Introduction of Private Payors will Further Drive Acceleration For personal use only Two main drivers of Private Payors are: 1 Global Clinical Trial Data • IPD’s own 1,100 patient post approval trial Nearly fully enrolled (5 top 50 cancer centres and 3 NCCN institutions are participants in trial)
Slide 11: Chronic Heart Failure
For personal use only Chronic Heart Failure
Slide 12: CHF Overview
CHF Overview For personal use only CHF is a chronic, progressive and debilitating condition Among the most expensive diseases for the US health care system US government funding Reducing hospital bonuses and assessing 6.5m+ US$31bn+ stay and readmission penalties for physicians patients hospitalisat
Slide 13: Role of SOZO in Optimising Outcomes for CHF Patient Management
Role of SOZO™ in Optimising Outcomes for CHF Patient Management For personal use only • Current practice is to monitor CHF patients daily for fluid burden both in clinic and at-home • Current monitoring methods have major shortcomings: Weight Scale • Inaccurate and rudimentary (although low cost – ~
Slide 14: Heart Failure Program Making Rapid Progress Towards Commercialisation in EU and US
Heart Failure Program Making Rapid Progress Towards Commercialisation in EU and US For personal use only SOZOTM Regulatory Preparations • CE Mark achieved in June 2017 • Submitting for FDA 510(k) clearance for CHF in Q3/Q4 CY2017 Clinical Data for Marketing Purposes • Working with world leading inst
Slide 15: CHF Business Model
CHF Business Model For personal use only Expected CHF Business Model Initial focus on Class III CHF patients Preliminary Estimate of Initial US Addressable Market • Estimated at 25% of US 6.5 million CHF patients • Monitor and manage the disease progression for Class III patients Estimated initial p
Slide 16: SOZO Approved and Launched in Australia and Europe
SOZOTM Approved and Launched in Australia and Europe For personal use only • Australia Strong initial enquiry, both existing and new customers • Large Institutional Clients • Physiotherapists • Distributors Cancer focused Medical Initial units shipped • To select practices and institutions •
Slide 17: Expected News Flow
Expected News Flow For personal use only L-Dex® adoption and revenue growth • FDA clearance for SOZO™ for lymphoedema – catalyst for significant acceleration in US sales • First data from Vanderbilt PREVENT trial • Private payors to begin coverage of L-Dex® - catalyst for broad adoption in US • Cont
Slide 18: Appendix
18 For personal use only Appendix
Slide 19: Management Team
Management Team For personal use only Deep and Broad Commercialisation Experience Richard Carreon Frank Vicini, MD Morten Vigeland David Adams Catherine Kingsford Dennis Schlaht Managing Director and Chief Medical Officer Chief Financial Officer SVP Ventures, SVP Medical Affairs SVP Quality, R&D Chi
Slide 20: Board of Directors
Board of Directors For personal use only Cherrell Hirst AO Gary Goetzke Scott R. Ward Richard Carreon Judith Downes Donald A. Williams Amit R. Patel FTSE, MBBS, BEdSt, Juris Doctorate MS, BSc Managing Director and Non-Executive Director BAcy, CPA MBA, BME D.Univ (Hon), FAICD Non-Executive Director N
Slide 21: World Renowned Medical Advisory Board
World Renowned Medical Advisory Board from Leading US CHF Institutions For personal use only US Advisory Board Members and Clinical Research Team Paul Friedman, MD Roy Small, MD FACC, FSCAI J. Thomas Heywood, MD Andrew Accardi, MD Laura Mauri, MD, MSc • Vice Chair, Department of • Medical Director o
Slide 22: Financials YTD
Financials YTD For personal use only For the Twelve Months Ended 30 June 2017 (Unaudited and Preliminary) Oncology Revenue (000’s) Cash Balance (000’s) Market Cap (millions) 22